Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘LIF’

It is becoming increasing obvious in these challenging times as the pandemic spreads globally that no corner of the earth (except perhaps the Antartica) is being left untouched.  As lockdowns begin or continue depending the phase the spread is at, this also has numerous implications for clinical trials, both academic and company funded studies alike.

Which direction should we be considering for early anti-cancer therapeutics?

One of the broader effects of the coronavirus pandemic likely means we won’t see much new data on many of the clinical trials after the currently scheduled presentations for AACR, ASCO, ESMO and ASH for a while yet, perhaps well in to 2021, which in turn is a strong reminder if we want to see how much progress is being made then we need to look at what data is available now.

I can well imagine many folks are already completely Zoomed or WebExed out from constant online meetings dealing with the implications of the pandemic on research and clinical development, as well as what happens to new and existing trials, so the idea of listening to two days of a virtual meeting on top is probably a bit daunting for the time-challenged observers amongst you.

AACR’s virtual meeting is a wonderful opportunity for smart folks to take some careful snapshots of where we are now, and how some of the early pipeline agents are shaping up.

The good news is we while your online internal meetings continue apace, we will be posting many reviews, summaries, discussion and analysis of the data here on BSB, hopefully sparing many of the additional stress in busy times. We plan to make the process of analysis and commentary relatively easy so you can follow along with us.

For reference, you can access all of our ongoing AACR20 conference coverage here. Future posts will also be added to this magazine page as they are posted.

In our fourth AACR Preview series, we take a keen look at some additional early products in development of interest, as we continue our updates on the never ending oncology R&D journey.

We highlight 10 emerging agents in early stage development to watch out for…some are new and others we previously reviewed preclinically and have moved along in their R&D journey into the clinic, with good and bad results to think about.

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the first annual AACR virtual meeting subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Barcelona: What makes a great scientist is not accepting conventional wisdom or dogma but instead thinking differently, pursuing what data generated truly means, and asking if we can do things differently as a result?

Gaudi architecture, Barcelona

Current success in immuno-oncology new product development has been built on basic research done twenty and thirty years ago, when many didn’t believe in leveraging the power of the immune system therapeutically.

At the ongoing European Association for Cancer Research (EACR) “Defense is the Best Attack” meeting in Barcelona this week, many experts in the IO field are sharing novel findings on what may lead to future insights.

What were some of the key take-homes?

Subscribers can read our notes from some of the presentations that stood out at the meeting.

If you’re not yet a BSB subscriber and are interested in learning from our science and clinical commentary/analysis then come join a growing band of enthusiastic readers!

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

With the annual meeting of Society for Immunotherapy of Cancer (SITC) fast approaching this week, it’s time for a look at some of the final highlights to watch out for.

National Harbor from Gaylord HotelIn this latest conference preview, we have chosen a dozen key topics of interest that readers may find worth checking out plus an honourable mention for early compounds in development that we may well hear more about going forward.

Some of the early warning signs were offered up in the earlier Previews and with the abstracts now available, things are getting very interesting indeed…

How are things panning out so far with the abstract drop and are the new products in development living up to the hype and expectations?

To learn more insights on the latest Gems from the Poster Hall series, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Before we move on to the Society for Immunotherapy of Cancer (SITC) meeting later this week, it’s time to wrap up the exciting AACR-NCI-EORTC molecular targets conference, which along with the CRI-CIMT-EATI-AACR international cancer immunotherapy conference in Mainz, have been my two favourite oncology meetings of the year so far.

Who would have predicted that back in January?

A scoot around the narrow #Targets17 poster hall…

It would be hard not to close out coverage without a popular Gems from the Poster Halls post.

Typically, we have focused this theme from cancer conferences around the following:

  • A new target
  • An interesting molecule
  • Intriguing basic or translational science of note
  • A particular tumour type
  • Insightful sentiments from thought leaders

In this latest version, we have examples of each.  We also have my favourite quote and discussion from the meeting, which perhaps not surprisingly, comes from a CAR T cell therapy discussion.

To learn more insights on the latest Gems from the Poster Hall series, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!